Author + information
- Received August 24, 2010
- Revision received October 25, 2010
- Accepted November 8, 2010
- Published online February 8, 2011.
- Jennifer L. Hall, PhD⁎,†,‡,⁎ (, )
- David R. Fermin, MD§,
- Emma J. Birks, MD∥,
- Paul J.R. Barton, PhD¶,#,
- Mark Slaughter, MD⁎⁎,
- Peter Eckman, MD⁎,
- Hideo A. Baba, MD††,
- Jeremias Wohlschlaeger, MD†† and
- Leslie W. Miller, MD‡‡
- ↵⁎Reprint requests and correspondence:
Dr. Jennifer L. Hall, University of Minnesota, 310 Church Street, Minneapolis, Minnesota 55455
The use of left ventricular assist devices in treating patients with end-stage heart failure has increased significantly in recent years, both as a bridge to transplantation and as destination therapy in those who are ineligible for cardiac transplantation. This increase is based largely on the results of several recently completed clinical trials with the new second-generation continuous-flow devices that showed significant improvements in survival, functional capacity, and quality of life. Additional information on the use of the first- and second-generation left ventricular assist devices has come from a recently released report spanning the years 2006 to 2009, from the Interagency Registry for Mechanically Assisted Circulatory Support, a National Heart, Lung, and Blood Institute–sponsored collaboration between the U.S. Food and Drug Administration, the Centers for Medicare and Medicaid Services, and the scientific community. The authors review the latest clinical trials and data from the registry, with tight integration of the landmark molecular, cellular, and genomic research that accompanies the reverse remodeling of the human heart in response to a left ventricular assist device and functional recovery that has been reported in a subset of these patients.
- clinical trials
- gene expression
- ventricular assist device
This work was funded in part by the National Institute for Health Research Cardiovascular Biomedical Research Unit at the Royal Brompton and Harefield National Health Service Foundation Trust and Imperial College (Dr. Barton), grants 0515584Z and 0655582Z from the American Heart Association, grant NIH-RO1-HL065462-04 from the National Institutes of Health, and the Lillehei Scholar Program (laboratory of Dr. Hall). Dr. Hall consulted for Catholic Health Care West from January 2008 to September 2010. Dr. Birks has received research support and honoraria from Thoratec. Dr. Slaughter has received research grant support from Heartware Inc. and Thoractec. Dr. Eckman has received consulting, honoraria, and research support from Thoratec. Dr. Baba has received speaker fees from Medtronic. Dr. Miller has received research support and speaking honoraria from Heartware Inc. and Thoratec. All other authors have reported that they have no relationships to disclose. W. H. Wilson Tang, MD, served as Guest Editor for this paper.
- Received August 24, 2010.
- Revision received October 25, 2010.
- Accepted November 8, 2010.
- American College of Cardiology Foundation